Specialty Medicine Meets Artificial Intelligence

Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I have spent 15+ years running Pharma Commercial Operations for three large Pharma organizations, managing ex-US markets and all therapeutic areas. I specialize in Commercial Execution, Go-to-market strategy, Launch Planning, Omnichannel Orchestration, Sales Operations, Incentive Compensation, Forecasting, Competitive Intelligence, Pricing & Contracts, etc.

Q2. How do factors such as unmet medical needs, treatment complexity, and payer landscape influence the AI-driven commercial opportunity sizes within specific specialty therapy areas?

Pharma specialities exhibit differing payer and prescriber characteristics. The commercial opportunity/market size is fairly well understood - with or without AI. What changes with the application of AI, though, are customer journey/orchestration strategies, faster generation of regulatory evidence such as global value dossiers, clinical trial protocol generation, etc., driving quicker and more effective go-to-market strategies.

Q3. Which specialty medicine subsegments or geographies exhibit high potential driven by AI-enabled commercial insights and tailored marketing strategies?

Specialty medicine subsegments that exhibit the highest AI enablement potential are the ones with fewer payers and practitioners - like Ophthalmology, Urology, Neonatal medicine, etc. In terms of geographies, the US takes the lead here having…